People: Emergent BioSolutions Inc (EBS.N)
EBS.N on New York Stock Exchange
17.85USD
2 Aug 2013
17.85USD
2 Aug 2013
Price Change (% chg)
$-0.04 (-0.22%)
$-0.04 (-0.22%)
Prev Close
$17.89
$17.89
Open
$17.87
$17.87
Day's High
$17.87
$17.87
Day's Low
$17.79
$17.79
Volume
2,108
2,108
Avg. Vol
49,557
49,557
52-wk High
$18.25
$18.25
52-wk Low
$12.50
$12.50
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Fuad El-Hibri |
54 | 2012 | Executive Chairman of the Board |
Daniel Abdun-Nabi |
57 | 2012 | President, Chief Executive Officer, Director |
Robert Kramer |
55 | 2012 | Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer |
Steven Chatfield |
55 | 2013 | Executive Vice President - Strategic Investments |
Adam Havey |
41 | 2011 | Executive Vice President, President - BioDefense Division |
Ronald Richard |
56 | 2011 | Lead Independent Director |
Sue Bailey |
68 | 2007 | Independent Director |
Zsolt Harsanyi |
68 | 2004 | Independent Director |
George Joulwan |
73 | 2013 | Independent Director |
John Niederhuber |
74 | 2010 | Independent Director |
Louis Sullivan |
79 | 2011 | Independent Director |
Marvin White |
50 | 2010 | Independent Director |
Robert Burrows |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Fuad El-Hibri |
Mr. Fuad El-Hibri is the Executive Chairman of the Board of Emergent BioSolutions Inc. From June 2004 to March 2012, Mr. El-Hibri served as chief executive officer and as chairman of board of directors. Mr. El-Hibri previously served as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of corporate reorganization, BioPort became a wholly owned subsidiary of Emergent BioSolutions and was subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri is chairman of East West Resources Corporation, a venture capital and business consulting firm, a position he has held since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University, a member of the board of directors of the U.S. Chamber of Commerce, a member of the advisory board of the Yale Healthcare Conference, a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the National Institutes of Health, or NIH, Oxford University and Cambridge University, a member of the board of trustees of the National Health Museum, a non-profit institution developing a museum of health sciences, and a member of the advisory board of the Heifetz International Music Institute, a non-profit organization dedicated to helping develop the skills of young musicians. He also serves as chairman of the El-Hibri Charitable Foundation. Mr. El-Hibri received a master’s degree in public and private management from Yale University and a B.A. in economics from Stanford University. |
Daniel Abdun-Nabi |
Mr. Daniel J. Abdun-Nabi has been appointed as President, Chief Executive Officer, Director of Emergent BioSolutions Inc., effective April 1, 2012. From May 2007 to March 2012, Mr. Abdun-Nabi served as president and chief operating officer. Mr. Abdun-Nabi previously served as secretary from December 2004 to January 2008, senior vice president, corporate affairs and general counsel from December 2004 to April 2007 and vice president and general counsel from May 2004 to December 2004. Mr. Abdun-Nabi served as general counsel for IGEN International, Inc., a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as senior vice president, legal affairs, general counsel and secretary of North American Vaccine, Inc. Mr. Abdun-Nabi received an M.L.T. in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst. |
Robert Kramer |
Mr.Robert G. Kramer Sr., is Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer of Emergent BioSolutions Inc., effective from December 3, 2012. Mr. Kramer has served as executive vice president, corporate services division since September 2012. Mr. Kramer was a consultant to the company from September 2011 through August 2012, serving as interim executive vice president, biosciences division from September 2011 to December 2011 and as interim executive vice president, corporate services division from January 2012 to August 2012. Prior to that, Mr. Kramer had served as executive vice president of manufacturing operations from April 2007 through January 2008, as president and chief executive officer of Emergent BioDefense Operations Lansing Inc., formerly BioPort Corporation, from July 2004 through January 2009, and in a number of advisory capacities from January 2009 until his retirement in March 2010. Mr. Kramer originally joined BioPort in February 1999, serving as chief financial officer of BioPort until August 2000, as chief operating officer of BioPort from September 2000 to June 2004 and as president of BioPort from October 2001 to June 2004. Prior to joining BioPort, Mr. Kramer served in various financial management positions at Pharmacia Corp., which was subsequently acquired by Pfizer Inc., and with subsidiaries of Northwest Industries. Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University. |
Steven Chatfield |
Dr. Steven N. Chatfield, Ph.D., is Executive Vice President - Strategic Investments of Emergent BioSolutions Inc., effective April 1, 2013. He is no longer Executive Vice President, President - BioSciences Division effective April 1, 2013. Dr. Chatfield previously served as senior vice president strategic investments from March 2010 to December 2011 and senior vice president biodefense from December 2009 to March 2010. From September 2007 through November 2009, Dr. Chatfield served as executive director of the centre for emergency preparedness and response of the U.K. Health Protection Agency. Prior to joining the U.K. Health Protection Agency, Dr. Chatfield served as Emergent’s chief scientific officer from January 2005 to August 2007 and as president of wholly owned subsidiary, Emergent Product Development UK Limited from June 2005 to August 2007. Dr. Chatfield served as development director and chief scientific officer of Microscience Limited, a U.K. biotechnology company, from March 1999 to December 2004. The Company acquired Microscience in June 2005. Prior to joining Microscience, Dr. Chatfield held various positions in the field of vaccine research and development, including director of biotechnology at Medeva plc, director of research at Evans Medical and several positions at Wellcome Biotechnology and the Wellcome Foundation. Dr. Chatfield received a Ph.D. from the Council for National Academic Awards in association with the University of Birmingham in the United Kingdom. |
Adam Havey |
Mr. Adam Havey is an Executive Vice President, President - BioDefense Division of Emergent BioSolutions Inc since March 2011. Mr. Havey previously served as president of Emergent BioDefense Operations Lansing LLC from January 2009 to February 2011; vice president of business operations from November 2007 to December 2008; and senior director of manufacturing development from June 2006 to November 2007. Mr. Havey received a B.S. in chemical engineering from Michigan State University. |
Ronald Richard |
Mr. Ronald B. Richard is an Lead Independent Director of Emergent BioSolutions Inc. Mr. Richard has served as the president and chief executive officer of the Cleveland Foundation, the nation’s oldest community foundation, since June 2003. From August 2002 to February 2003, Mr. Richard served as president of Stem Cell Preservation, Inc., a start-up medical research company. After leaving Stem Cell Preservation and prior to joining Emergent BioSolutions, Mr. Richard served as a strategic business advisor for IGEN International, Inc., a biotechnology company. Mr. Richard served as chief operating officer of In-Q-Tel, a venture capital fund that provides technologies to the Central Intelligence Agency, from March 2001 to August 2002. Prior to joining In-Q-Tel, Mr. Richard served in various senior management positions at Matsushita Electric (Panasonic), a consumer electronics company. Mr. Richard is a former U.S. foreign service officer. He served in Osaka/Kobe, Japan and as a desk officer for North Korean, Greek and Turkish affairs at the U.S. Department of State in Washington, D.C. Mr. Richard previously served as chairman of the board of trustees of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. Mr. Richard received an M.A. in international relations from Johns Hopkins University School of Advanced International Studies and a B.A. in history from Washington University. He holds an honorary doctorate in humane letters from Notre Dame College. |
Sue Bailey |
Dr. Sue Bailey, M.D., is an Independent Director of Emergent BioSolutions Inc since June 2007. Dr. Bailey served as a news analyst for NBC Universal, a media and entertainment company, from November 2001 to August 2006. Previously, Dr. Bailey served as Administrator, National Highway Traffic Safety Administration, as Assistant Secretary of Defense (Health Affairs) and as Deputy Assistant Secretary of Defense (Clinical Services). Dr. Bailey is a former faculty member at Georgetown Medical School and U.S. Navy officer, having achieved the rank of Lt. Commander, U.S. Navy Reserve. Dr. Bailey received her D.O. from Philadelphia College of Osteopathic Medicine and a B.S. from the University of Maryland. |
Zsolt Harsanyi |
Dr. Zsolt Harsanyi, Ph.D., is an Independent Director of Emergent BioSolutions Inc since August 2004. Dr. Harsanyi has served as a director since August 2004. Dr. Harsanyi has served as chief executive officer and chairman of the board of directors of Exponential Biotherapies Inc., a private biotechnology company, since December 2004. Dr. Harsanyi served as president of Porton International plc, a pharmaceutical and vaccine company, from January 1983 to December 2004. Dr. Harsanyi was a founder of Dynport Vaccine Company LLC in September 1996. Prior to joining Porton International, Dr. Harsanyi was vice president of corporate finance at E.F. Hutton, Inc. Previously, Dr. Harsanyi directed the first assessment of biotechnology for the U.S. Congress’ Office of Technology Assessment, served as a consultant to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research and was on the faculties of Microbiology and Genetics at Cornell Medical College. Dr. Harsanyi received a Ph.D. from Albert Einstein College of Medicine and a B.A. from Amherst College. |
George Joulwan |
General George A. Joulwan has been appointed as Independent Director of Emergent BioSolutions Inc., effective July 17, 2013. General Joulwan served in numerous leadership positions in the U.S. Army, the Pentagon, and as a special assistant to the President of the United States, after completing two combat tours in Vietnam. During his career, General Joulwan played a key role in pivotal historical moments, including: securing peace and stability in Germany during and after the fall of the Berlin Wall; bringing peace to El Salvador and democracy to Panama; professionalizing the militaries of Latin America; developing the first strategic policy for U.S. military engagement in Africa; orchestrating the State Partnership Program linking American Reserve Forces with former non-NATO countries and newly independent democracies of Europe and the former Soviet Union; architecting the Bosnia operation, and acting as the senior NATO commander overseeing the NATO-led Dayton Peace Agreement. His work with NATO operations became the basis for the historic NATO-Russian Founding Act that ended the Cold War. General Joulwan serves on company and charitable boards, was a professor at the United States Military Academy at West Point, and served on the Board of Trustees for the United States Military Academy. General Joulwan is a United States Military Academy graduate, and earned his master's degree in political science and an honorary doctor of laws degree from Loyola University in Chicago. |
John Niederhuber |
Dr. John E. Niederhuber, M.D., is an Independent Director of Emergent BioSolutions Inc. Dr. Niederhuber has served as a director since August 2010. He previously served as the director of the National Cancer Institute, or NCI, from 2005 to 2010. Dr. Niederhuber joined Inova Health System in August 2010 as Executive Vice President and CEO of the Inova Institute for Translational Research and Personalized Medicine. Dr. Niederhuber is also an adjunct investigator at NCI’s Center for Cancer Research, studying factors in the tumor microenvironment that lead to increased malignancy. Prior to joining NCI, Dr. Niederhuber was Director of the University of Wisconsin Comprehensive Cancer Center and a professor of surgery and oncology (member of the McArdle Laboratory) at the University of Wisconsin School of Medicine from 1997 to 2005. He chaired the Department of Surgery at Stanford University from 1991 to 1997 and held professorships at the Johns Hopkins University School of Medicine from 1987 to 1991 and at the University of Michigan from 1973 to 1987. Dr. Niederhuber is a graduate of Bethany College in West Virginia and the Ohio State University School of Medicine. He trained in surgery at the University of Michigan. |
Louis Sullivan |
Dr. The Hon. Louis W. Sullivan, M.D., is Independent Director of Emergent BioSolutions Inc. Dr. Sullivan has served as president emeritus of Morehouse School of Medicine since July 2002. Dr. Sullivan served as president of Morehouse School of Medicine from 1981 to 1989 and from 1993 to 2002. From 1989 to 1993, Dr. Sullivan was Secretary of the Department of Health and Human Services. Dr. Sullivan serves on the boards of directors of United Therapeutics Corporation, BioSante Pharmaceuticals and Henry Schein, Inc., all publicly held biotechnology companies. He was a founder and chairman of Medical Education for South African Blacks, Inc., a trustee of Africare, a director of the National Center on Addiction and Substance Abuse at Columbia University and chairman of the board of trustees of the National Health Museum, a non-profit institution developing a museum of health sciences. Dr. Sullivan received his M.D. from Boston University and a B.S. from Morehouse College. |
Marvin White |
Mr. Marvin L. White is an Independent Director of Emergent BioSolutions Inc since June 2010. Mr. White is currently system vice president and chief financial officer of St. Vincent Health, and is responsible for finance, materials management, accounting, patient financial services and managed care for all 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was executive director and chief financial officer of LillyUSA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking in the Corporate Strategy Group. He serves on the boards of Marian University and Advantage Health Solutions, Inc., and has been active with the Center for Leadership Development, Saving Orphans through Healthcare and Outreach (SOHO) and with the United Way. Mr. White earned his B.A. in Accounting from Wilberforce University, and an M.B.A. in Finance from Indiana University. |
Robert Burrows |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Fuad El-Hibri |
3,221,220 |
Daniel Abdun-Nabi |
1,752,560 |
Robert Kramer |
664,493 |
Steven Chatfield |
507,128 |
Adam Havey |
897,699 |
Ronald Richard |
-- |
Sue Bailey |
-- |
Zsolt Harsanyi |
-- |
George Joulwan |
-- |
John Niederhuber |
-- |
Louis Sullivan |
-- |
Marvin White |
-- |
Robert Burrows |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Fuad El-Hibri |
135,333 | 554,853 |
Daniel Abdun-Nabi |
210,448 | 2,678,520 |
Robert Kramer |
670,028 | 4,286,840 |
Steven Chatfield |
77,542 | 534,953 |
Adam Havey |
6,667 | 105,539 |
Ronald Richard |
0 | 0 |
Sue Bailey |
0 | 0 |
Zsolt Harsanyi |
0 | 0 |
George Joulwan |
0 | 0 |
John Niederhuber |
0 | 0 |
Louis Sullivan |
0 | 0 |
Marvin White |
0 | 0 |
Robert Burrows |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
JOULWAN GEORGE A |
5,400 | $0.00 |
EL HIBRI FUAD |
347,488 | $0.00 |
ABDUN NABI DANIEL J |
800 | $12.07 |
KRAMER ROBERT G SR |
58,249 | $0.00 |
RICHARD RONALD B |
3,600 | $0.00 |
HARSANYI ZSOLT |
3,600 | $0.00 |
NIEDERHUBER JOHN |
3,600 | $0.00 |
WHITE MARVIN L |
3,600 | $0.00 |
BAILEY SUE |
3,600 | $0.00 |
SULLIVAN LOUIS W |
3,600 | $0.00 |
EL HIBRI FUAD |
62,851 | $15.05 |
EL HIBRI FUAD |
52,021 | $15.02 |
HAVEY ADAM |
1,046 | $14.46 |
ABDUN NABI DANIEL J |
2,248 | $14.46 |
CHATFIELD STEVEN N |
1,008 | $14.46 |
EL HIBRI FUAD |
3,659 | $14.46 |
HAVEY ADAM |
11,939 | $0.00 |
ABDUN NABI DANIEL J |
3,201 | $14.67 |
KRAMER ROBERT G SR |
3,940 | $0.00 |
HAVEY ADAM |
820 | $14.67 |
CHATFIELD STEVEN N |
1,833 | $14.67 |
EL HIBRI FUAD |
20,902 | $0.00 |
EL HIBRI FUAD |
1,463 | $14.67 |
ABDUN NABI DANIEL J |
40,834 | $0.00 |
CHATFIELD STEVEN N |
11,939 | $0.00 |

